Burlington, Massachusetts, November 10, 2020 — MilliporeSigma today announced that its first-to-market Blazar™ platform from the BioReliance® portfolio has won R&D 100 and CPhI Awards for its ability to reduce testing times by up to 80 percent. MilliporeSigma’s Bio4C™ ProcessPad, part of the company’s expanding BioContinuum™ Platform, also made the shortlist for the 2020 CPhI Awards. These awards honor the latest and best innovations, identifying the top products of the past year.
“MilliporeSigma is providing advanced products and services that help bring important drug therapies to market, faster,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma. “Our advancements set the standard for how drug production is done today and shape the possibilities of tomorrow.”
The company has been a key driver of the industry’s evolution to BioProcessing 4.0, which uses advanced digital and process technologies to offer a step change in productivity.
MilliporeSigma’s Blazar™ platform earned the 2020 CPhI Pharma Award in the Analysis, Testing and Quality Control category. The first-to-market platform was also named a winner in the 2020 R&D 100 Awards’ Analytical/Test category. This technology represents a fundamental shift in biosafety testing within the industry toward rapid molecular methods, reducing testing time by up to 80 percent, or to as little as seven days. The platform can detect a broad range of viruses and is well-suited to cell line characterization and bulk-harvest lot release testing.
MilliporeSigma’s Bio4C™ ProcessPad made the shortlist for the 2020 CPhI Pharma Awards’ Digital Innovation category. The Bio4C™ ProcessPad, part of the “Collect” dimension of the Bio4C™ Suite, is a browser-based platform that allows users to acquire, aggregate and analyze data from disparate sources such as equipment, batch records, databases and historians across the bioprocess. The Bio4C™ ProcessPad automates data acquisition and analysis tasks, freeing scientists and engineers to minimize the time to decision and action. With more than 65 years of experience in downstream processing, MilliporeSigma offers an expansive range of technologies and services to help tackle downstream processing challenges from development to full-scale production.
MilliporeSigma is committed to helping its customers deliver lifesaving therapies to more patients, faster, by increasing efficiencies and reducing costs.
About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 23,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany generated sales of € 17.5 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
To continue reading please sign in or create an account.Don't Have An Account?